Clinical Protocols

Oncology Division

Oncology Clinical Trials

 

 

Hematology Division

Click on the title of a protocol to view its description in ClinicalTrials.gov.
 

Disease Protocol (Sponsor) Status PI/Contact Comments
TTP/microangiopathy TITAN Phase II Single-Blind Randomized Placebo Controlled Trial to Study Efficacy and Safety of Anti-VWF Nanobody in Patients with Acquired TTP (Ablynx) Open PI: Morey Blinder
Contact: Morey Blinder
mblinder@dom.wustl.edu
Suspected TTP prior to starting PEx
ITP Randomized Trial with Open-Label Extension to Evalulate the Efficacy and Safety of Oral E5501 vs. Eltrombopag in Adults with ITP (Eisai) Open PI: Morey Blinder
Contact: Morey Blinder
mblinder@dom.wustl.edu
Relapsed ITP
Iron overload/MDS TELESTO A Multicenter, Randomized, Double-Blind Placebo Controlled, Clinical Trial of Desferasirox in Patients with MDS (Low/Int-1 risk) and Transfusional Iron Overload (Novartis) Open PI: Morey Blinder
Contact: Morey Blinder
mblinder@dom.wustl.edu
Low/Int-1 MDS Transfusion Dependent
Iron deficiency Distribution of Iron Isotopes 56Fe and 54Fe in the Serum of Iron Deficiency Anemia and Anemia of Chronic Disease Patients (Internal) Open PI: Mitch Scott
Contact: Morey Blinder
mblinder@dom.wustl.edu
Suspected iron deficiency of ACD in pre-menopausal women
Thrombosis ATTRACT (NIH) Open PI: Suresh Vedantham
Contact: Morey Blinder
mblinder@dom.wustl.edu
New DVT
Atypical HUS Registry of patients with atypical HUS Open PI: Elaine Majerus
Contact: Shatesha Boyce
boyces@wustl.edu
Atypical HUS
Banking Laboratory Studies Blood Acquistion for Investigation of Thrombotic Disorders (NIH) Open PI: Elaine Majerus
Contact: Shatesha Boyce
boyces@wustl.edu
Thrombosis Banking
PNH PNH Registry (Alexion) Open PI: Elaine Majerus
Contact: Shatesha Boyce
boyces@wustl.edu
PNH Registry
Hemophilia/Bleeding American Thrombosis and Hemostasis Network Data Collection Open PI: Elaine Majerus
Contact: Bill Berger
bberger@wustl.edu
Sickle Cell Disease NKTT Phase 1 Trial of a Monoclonal Antibody Against NK T Cells Open PI: Elaine Majerus Hb SS and S Beta Null
Sickle Cell Disease Phase II Trial of Regadenoson as an Inhibitor of NK T Cells in the Treatment of Sickle Cell Crisis Open PI: Elaine Majerus HbSS and S Beta Null
Polycythemia vera Randomized, open label, multicenter phase III study of efficacy and safety in polycythemia vera subjects who are resistant to or intolerant of hydroxyurea: JAK inhibitor INC424 tablets versus best available care (The RESPONSE Trial) Open PI: Stephen Oh
Contact: Karyn Gordon
kgordon@dom.wustl.edu
314-362-0156
Ruxoltinib for PV patients resistant/intolerant to HU
Polycythemia vera Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes (The RELIEF Study) (Incyte) Open PI: Stephen Oh
Contact: Karyn Gordon
kgordon@dom.wustl.edu
314-362-0156
Ruxolitinib vs HU for symptomatic PV patients
Polycythemia vera or ET A Randomized Phase II, Open-Label study of the Efficacy and Safety of Orally Administered SAR302503 in patients with polycythemia vera (PV) or essential thrombocythemia (ET) who are resistant or intolerant to hydroxyurea (Sanofi) Open PI: Stephen Oh
Contact: Karyn Gordon
kgordon@dom.wustl.edu
314-362-0156
JAK inhibitor for PV or ET patients resistant/intolerant to HU
Myelofibrosis A Phase 2 Study to Evaluate the Efficacy and Safety of GS-6624 in Adult Subjects with Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis (Gilead) Open PI: Stephen Oh
Contact: Karyn Gordon
kgordon@dom.wustl.edu
314-362-0156
LOXL2 mAb (anti-fibrotic) alone or in combination with ruxolitinib
Chuvash polycythemia Ruxoltinib for Chuvash Polycythemia Open PI: Stephen Oh
Contact: Karyn Gordon
kgordon@dom.wustl.edu
314-362-0156
Compassionate-use study with ruxolitinib for Chuvash polycythemia
TTP/microangiopathy Adjuvant Low Dose Rituximab for Acquired TTP with Severe ADAMTS-13 Deficiency Open PI: Evan Sadler
Contact: Leili Dolatshahi
dolatshahi_l@wustl.edu
Low dose Rituximab for TTP